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Abstract
Background: This study was conducted in order to elucidate metabolic differences between human
rectal cancer biopsies and colorectal HT29, HCT116 and SW620 xenografts by using high-resolution
magnetic angle spinning (MAS) magnetic resonance spectroscopy (MRS) and for determination of the most
appropriate human rectal xenograft model for preclinical MR spectroscopy studies. A further aim was to
investigate metabolic changes following irradiation of HT29 xenografts.
Methods: HR MAS MRS of tissue samples from xenografts and rectal biopsies were obtained with a
Bruker Avance DRX600 spectrometer and analyzed using principal component analysis (PCA) and partial
least square (PLS) regression analysis.
Results and conclusion: HR MAS MRS enabled assignment of 27 metabolites. Score plots from PCA of
spin-echo and single-pulse spectra revealed separate clusters of the different xenografts and rectal
biopsies, reflecting underlying differences in metabolite composition. The loading profile indicated that
clustering was mainly based on differences in relative amounts of lipids, lactate and choline-containing
compounds, with HT29 exhibiting the metabolic profile most similar to human rectal cancers tissue. Due
to high necrotic fractions in the HT29 xenografts, radiation-induced changes were not detected when
comparing spectra from untreated and irradiated HT29 xenografts. However, PLS calibration relating
spectral data to the necrotic fraction revealed a significant correlation, indicating that necrotic fraction can
be assessed from the MR spectra.
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Background
Animal models are frequently used in the study of com-
plex human diseases. With the use of new technology and
the availability of transgenic animals, molecular mecha-
nisms of several diseases can be explored. In order for an
animal model to serve as a useful model for human dis-
ease, the modeled disease must be similar in etiology and
function to the human equivalent. Man-mouse xenografts
have been widely used to assess the therapeutic effect of
carcinostatic drugs on human malignant cells [1-3]. How-
ever, many drugs that show anti-tumor activity in subcu-
taneous (s.c.) xenograft models have shown
disappointing results in the clinics [4,5]. Characterization
of tissue at the molecular level will elucidate differences
and similarities between metabolic profiles of human rec-
tal cancer and xenografts. Knowledge of the metabolic
profile of a xenograft can be important for its predictive
value as tumor model in preclinical biomedical research.
In vivo proton magnetic resonance spectroscopy (1H MRS)
is used to elucidate biochemical profiles of tissues in a
number of disorders [6-8]. Limitations on the strength
and inherent inhomogeneity of the magnetic fields restrict
these studies to a handful of high-concentration metabo-
lites. Ex vivo 1H nuclear magnetic resonance (NMR) spec-
troscopy of excised tissue generate spectra that enable
separation and relative quantification of the majority of
metabolites in the tissue. But, due to the molecular con-
straints of semi-solids, ordinary high resolution (HR)
MRS of excised tissue results in broadening of the metab-
olite peaks in the MR spectra. As dipole couplings and
chemical shift anisotropy both are scaled according to the
term (3cos2θ-1), positioning the sample at the so-called
magic angle of 54.7° to the magnetic field and then spin-
ning it rapidly about its own axis, reduce these interac-
tions [9].
The first applications of HR MAS MRS on human tissue
specimens date back to 1997 when Moka et al. [10]
applied it to human kidney tissue, Millis et al. [11] to
human lipoma and liposarcoma tissue and Cheng et al.
[12] to human brain samples. HR MAS MR spectroscopy
has later been used in numerous studies of both healthy
and affected tissue, with the application to brain, breast
and prostate cancer tissue [13-15]. HR MAS MRS has a
potential to become a supplement in clinical diagnostics
[16,17]. To the authors knowledge, there are no studies
reported where HR MAS MRS has been used for biochem-
ical characterization of human colorectal tumor tissue.
The histological differences of tumors arising in mice
compared to those in humans have been a major limita-
tion of many mouse models. To select the appropriate
xenograft model, it is also important to know the geno-
and phenotypic differences between experimental animal
xenografts and human tumor tissue. In order to determine
the most appropriate human rectal cancer xenograft
model for preclinical MR spectroscopy, we used principal
component analysis for comparing the metabolic profile
of human rectal tumor biopsies with three common
colorectal cell lines using HR MAS MR spectroscopy. Fur-
thermore, we investigated the changes in biochemical
composition of HT29 xenografts following 15 Gy irradia-
tion.
Results
Spectral assignment
Representative CPMG spin-echo HR MAS MR spectra of
the colorectal xenografts SW620, HCT116 and HT29 are
presented in Fig. 1 together with the spin-echo spectra
from a human rectal adenocarcinoma biopsy. High spec-
tral resolution of the one dimensional spin-echo spectra
combined with reported data from the literature (18,19)
and two dimensional proton-proton spectroscopy (COSY,
Fig. 2) allowed identification and assignment of 27 differ-
ent metabolites (Table 1) between 4.7 and 0.5 ppm.
Amino acids, choline-containing compounds, creatine,
inositols and lactate dominated the spin-echo spectra.
Although lipids were the most dominant peaks in the sin-
gle-pulse spectra, the metabolites were clearly visible also
in the single-pulse spectra. In general, the HR MAS MR
spectra of the colorectal xenografts and the human rectal
cancer tissue contained the same metabolites and classifi-
cation was based on differences between the relative
amounts of the same metabolites. Glucose was either not
detectable or appearing in low levels in HCT116, SW620
and human tissue samples. In HT29 xenografts however,
glucose was detected in all samples with high levels in
some of them. Beta-hydroxybutyrate was only detected in
the human rectal biopsies.
Histology
Histological examination of HR MAS MRS analyzed tissue
from non-irradiated samples revealed large differences in
viable tumor cells, fibrosis and necrotic tissue (Table 2).
Whereas necrotic areas were found in all cross-sections
from xenografts, no necrosis was observed in human rec-
tal cancer tissue samples. The necrotic fractions varied
from 5 to 80% for the xenograft samples. However, one-
way ANOVA showed no significant differences between
the amounts of necrosis in the three untreated xenografts
(p = 0.49).
Comparison of metabolic profiles of xenografts and 
human rectal cancer
Score plot of the first principal component (PC1) versus
PC2 from PCA of the spin-echo spectra is shown in Fig.
3A. These two components describe 65% of the total var-
iation in the spectra. PCA demonstrates a grouping of
spectra from SW620, HCT116, HT29 and human rectalMolecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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Table 1: Chemical shift assignment.
Assigned number Metabolite Multiplicity ppm
1 Fatty acids CH3 t 0.89
(CH2)n m 1.31
CH2CH3 m 1.35
CH2CH2CO m 1.59
CH=CHCH2CH2 m 2.03
-CH2-CH2-CO- m 2.26
2 Isoleucine δCH3 t 0.95
γCH3 d 1.02
γCH m 1.46
βCH m 1.99
3L e u c i n e δ'CH3 d 0.95
δCH3 d 0.97
βCH m 1.71
αCH t 3.75
4 Valine γCH3 d 0.99
γ'CH3 d 1.04
βCH m 2.29
αCH d 3.62
5 Betahydroxybutyrate CH3 d 1.18
6 Lactate CH3 d 1.33
CH q 4.13
7 Alanine βCH3 d 1.48
αCH q 3.79
8 Lysine γCH2 m 1.48
δCH2 m 1.73
βCH2 m 1.92
εCH2 t 3.02
αCH2 t 3.79
9A c e t a t e C H 3 s 1.94
10 Glutamate βCH2 c 2.11
γCH2 t 2.34
αCH t 3.77
11 Glutamine βCH2 c 2.14
γCH2 c 2.45
αCH t 3.79
12 Succinate (α,βCH2)s 2 . 4 1
13 Aspartate βCH dd 2.71
β'CH dd 2.83
αCH dd 3.91
14 Tyrosine βCH dd 2.87
β'CH dd 2.96
αCH dd 4.02
15 Creatine CH3 s 3.04
CH2 s 3.94
16 Choline N(CH3)3 s 3.22
17 Phosphoethanolamine NCH2 dd 3.23
OCH2 dd 3.99
18 Phosphocholine N(CH3)3 s 3.23
NCH2 dd 3.62
OCH2 dd 4.18
19 Glycerophosphocholine N(CH3)3 s 3.24
20 Taurine N-CH2 t 3.24
S-CH2 t 3.42
21 β-Glucose C2H t 3.26
C5H dd 3.42
C6H d 3.85
C1H d 4.64
22 scyllo-Inositol (All Hs) s 3.35
23 myo-Inositol C5H t 3.27Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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cancer biopsies with the HT29 xenografts exhibiting the
metabolic profile most similar to human rectal cancer
biopsies. The variation in metabolic profile of human rec-
tal cancer tissue is small as seen by the clustering of the
spectra in the score plot. The loading profile of PC1
explains 40% of the total variation in the spectra. It shows
that differences in relative concentrations of lipids, lactate
and choline-containing compounds (Fig. 3B) are the
main reason for the appearance of the clusters. Spectra
with a high score value for PC1 have relatively lower levels
of cholines and higher levels of lipids and lactate. There is
large variation in PC2 for all xenograft species as well as
for the human rectal cancer biopsies and hence, PC2 con-
tributes minimally to clustering of the spectra. Color-cod-
ing the score plot with respect to histologically
determined necrotic fractions showed that differences in
necrotic fraction did not explain grouping of the spectra.
Despite single-pulse spectra being dominated by lipid sig-
nals, PCA of the single-pulse spectra showed similar clus-
tering in the score plot (Fig. 3C) as for the analysis of the
spin-echo spectra (Fig. 3A). For the single-pulse spectra
PC1 described 76% of the total variation in the spectra.
Although HT29 xenografts and human rectal cancer biop-
sies exhibit similar score values for PC1, their metabolic
profile is not identical as seen by the score plot of PC1 ver-
sus PC3 (Fig. 4A) and the loading profile of PC3 (Fig. 4B)
which describes 9% of the total variation in the spectra.
Compared to HT29 xenografts, human rectal biopsies
contain relatively higher amounts of lactate, taurine,
inositols, choline and less of glucose, creatine, phospho-
choline and glycerophosphocholine.
Metabolic profiles of irradiated and untreated HT29 
xenografts
In Fig. 5 the score plot of PC1 and PC2 from PCA of sin-
gle-pulse spectra (Fig. 5A and 5B) and the corresponding
loading profile of PC1 (Fig. 5C) of irradiated and
untreated HT29 xenografts are shown. PC1 and PC2
account for 79 and 8% of the total variation in the spectra,
respectively, and the differences between spectra are
mainly due to differences in relative lipid content of indi-
vidual samples. Spectra from two irradiated HT29
xenografts cluster together with the untreated xenografts
(Fig. 5A). Thus, a distinct separation of untreated and irra-
diated xenografts based on their spectral metabolic profile
is not accessible. The two irradiated tissue samples group-
ing together with the untreated biopsies had substantially
lower necrotic fractions than the other irradiated
xenografts as illustrated in Fig. 5B where the score plot
from Fig 5A is color-coded with respect to necrotic frac-
tion. This indicates a strong association between necrotic
fraction in the samples and their score for PC1.
By relating single-pulse spectra to the necrotic fraction
(both irradiated and untreated) using PLS, a strong corre-
lation was found between necrotic fraction predicted by
HR MAS MRS and by histology (Fig. 6A). PC1 and PC2
from PLS analysis accounted for 86% and 73% of the total
x- and y-variation, respectively (Fig. 6B). The loading pro-
file of PC1 was dominated by lipid signals and was almost
identical to the loading profile of PC1 from the analysis of
untreated and irradiated HT29 xenografts (Fig 6C). Thus,
radiation-induced therapy response was not detectable,
whereas necrotic fraction can be assessed from the spectral
data; samples with high necrotic fractions had high score
values for the first principal component (PC1) compared
to those with low necrotic fractions (Fig. 6B). PCA and
PLS of spin-echo spectra showed similar results as analysis
of single-pulse spectra (no plots shown).
Discussion
Xenografts in animals are valuable models in predicting
clinical outcome of therapeutic interventions. Molecularly
well-characterized xenografts may also serve as valuable
tools in target-orientated drug development of specific
rationally designed small molecules. Knowledge of the
differences in metabolic composition between tumors
arising in mice and those in humans might help selecting
the appropriate xenograft model. The human HT29,
HCT116 and SW620 cell lines are among the most com-
monly used models representing colorectal cancer [18].
To the authors knowledge this is the first HR MAS MRS
analysis and assignment of metabolites in rectal cancer.
The spectral information obtained by one-dimensional
C1H, C3H dd 3.52
C4H, C6H t 3.62
C2H t 4.07
24 Glycine αCH2 s 3.56
25 Amino acid residues αCH q 3.77
26 Triglycerides, glyceryl 1/2 CH2OCOR m 4.09
1/2 CH2OCOR m 4.31
27 Ascorbic acid C4H d 4.53
Tentative 1H chemical shift assignment of HR MAS MR spectra obtained from human rectal cancer tissue and xenografts. Chemical shift referencing 
is relative to TSP. Peak multiplicity is given as s: singlet, d:doublet, dd: double doublet, t: triplet, q: quartet, m: multiplet or c: complex. Assigned 
numbers correspond to the numbering in Fig. 1 and Fig 2.
Table 1: Chemical shift assignment. (Continued)Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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Representative high-resolution proton spectra (4.7 - 0.5 ppm) of SW620 (A), HCT116 (B), HT29 (C), and a human rectal ade- nocarcinoma biopsy (D) Figure 1
Representative high-resolution proton spectra (4.7 - 0.5 ppm) of SW620 (A), HCT116 (B), HT29 (C), and a 
human rectal adenocarcinoma biopsy (D). For display the spectral amplitude of the lactate doublet at 1.33 ppm have 
been cut. Assignments are given in Table 1.Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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HR MAS MR spectra of rectal adenocarcinoma (Fig. 1D)
showed resolution comparable to cell suspension [19]
and perchloric acid extract [20] spectra of colorectal can-
cer tissue previously described in high field 1H-NMR. The
HR MAS MR spectra were dominated by choline, lactate,
inositols, creatine and taurine. The choline metabolites
(choline, phosphocholine and glycerophosphocholine)
are important in the phospholipids metabolism [21] and
these metabolites can undergo extensive alterations result-
ing from malignant transformations [22-25]. For human
mammary epithelial cells progression from a normal to a
malignant phenotype is associated with a reversal in the
ratio of phosphatidylcholine and glycerophospho-
Partial homonuclear correlated spectrum (COSY) of tissue from HT29 xenograft (spectral region 4.7 - 0.5 ppm) Figure 2
Partial homonuclear correlated spectrum (COSY) of tissue from HT29 xenograft (spectral region 4.7 - 0.5 
ppm). The identified metabolites are denoted with labels according to Table 1.
Table 2: Tumor histology.
n Tumor cells [%] Necrosis [%] Fibrosis [%]
SW620 5 60 (30–70) 40 (10–60) 10 (0–20)
HCT116 7 70 (20–90) 10 (5–60) 20 (0–20)
HT29 8 65 (10–80) 15 (5–80) 20 (10–20)
Rectal cancer biopsies 10 35 (10–98) 0 (0-0) 28 (0–60)
Percentage viable tumor cells, necrosis and fibrosis in the HR MAS MRS analyzed tissue samples from untreated SW620, HCT116, HT29 and 
human rectal cancer biopsies. Results are given as median and range.Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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choline, as well as an overall increase in the content of
these two metabolites [22].
Taurine has been shown to be elevated in rectal adenocar-
cinoma compared to healthy mucosa [26], and thus a
potential tumor marker. Further studies are needed to
assess the full potential of HR MAS MRS in the diagnosis
and grading of rectal adenocarcinoma.
PCA of spectra from human rectal cancer tissue and HT29,
SW620 and HCT116 xenografts showed that the HT29
xenograft had the metabolic profile most similar to rectal
cancer biopsies. Nevertheless, there are differences in met-
abolic patterns of HT29 xenografts and human rectal can-
cer biopsies that could influence their usefulness as
preclinical tumor models. First, the human samples had
relatively higher lactate levels than the HT29 xenografts. If
the elevated tumor lactate level observed is a result of
hypoxic tumor environment, hypoxia-mediated radiation
resistance could lead to overestimation of the therapeutic
effect of chemotherapy and radiotherapy in a preclinical
model [27,28]. The HT29 xenografts also exhibited higher
levels of glycerophosphocholine and phosphocholine
and lower levels of choline than rectal cancer biopsies sug-
gesting an increased tumor proliferation rate and cell
membrane turnover through the activation of the phos-
phatidylcholine pathway in the xenografts [21]. The
amounts of choline metabolites differ between cell lines
Score plot of PC1 versus PC2 from PCA of spin-echo (A) and single pulse (C) spectra from untreated HT29, HCT116, SW620  xenografts and rectal cancer biopsies (A) Figure 3
Score plot of PC1 versus PC2 from PCA of spin-echo (A) and single pulse (C) spectra from untreated HT29, 
HCT116, SW620 xenografts and rectal cancer biopsies (A). The corresponding loading profiles of PC1 are shown next 
to the score plots (B and D).Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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and for breast cancer cells it has been proposed that this
distribution is linked to malignancy and metastatic poten-
tial [23,24]. Compared to human rectal cancers, the rap-
idly growing HT29 xenograft is poorly vascularized and
associated with subsequent development of hypoxic areas
and tumor aggressiveness.
Histological examination of the tissue samples revealed
large differences in necrotic fraction, viable cell fraction
and fibrosis between tissue samples. None of the human
colorectal cancer biopsies contained necrotic tissue,
whereas the necrotic fraction for the xenografts varied
between 5 and 80%. The non-existence of necrosis in the
human tissue samples in this study could be due to the
absence of necrosis in these human rectal cancers or
related to the biopsy procedure. We found no association
between the metabolic profile of non-irradiated tumors
and necrotic fractions, which confirms that the clustering
of spectra is based on true metabolic differences and not
on the amounts of necrosis within the samples.
PCA of spectra from irradiated HT29 xenografts and
untreated HT29 xenografts showed that two of the irradi-
ated samples clustered together with the untreated
tumors, probably due to the high necrotic fraction in these
two samples. Thus, in our study PCA could not be used to
evaluate treatment induced metabolic changes. A better
differentiation between viable and necrotic areas before
HR MAS to ensure that viable tumor tissue is investigated
will be necessary in order to detect the treatment induced
metabolic changes. Well-developed HT29 xenografts have
necrotic centers and an outer rim of viable cells. Selection
of tissue sample from these xenografts is critical and will
largely influence the results. Still, these sampling errors
are similar to those associated with other clinically used
invasive methods.
There was a strong correlation between necrotic fraction
and the metabolic profile of untreated and irradiated
HT29 xenografts. Differences in metabolic profiles were
based on their relative amount of necrosis rather than
radiation-induced effects. Furthermore, a significant cor-
relation was found between predicted and measured
necrotic fraction (r = 0.76, p < 0.002) (Fig. 6A), indicating
that the necrotic fraction in the sample can be assessed
from the samples metabolic profile.
Conclusion
A large number of metabolite peaks were identified and
assigned in the HR MAS MR spectra of human colorectal
cancer and xenograft parallels. By PCA calibration, differ-
ences in the metabolic composition between HT29,
HCT116 and SW620 xenografts and human rectal cancers
were revealed. HT29 xenografts were found to have the
metabolic profile most similar to human rectal tissue
biopsies. The necrotic fraction in the xenografts affects the
metabolic profile and in order to assess treatment-
induced metabolic changes investigation of only viable
tumor tissue should be ensured.
Methods
Animals and xenografts
Xenografts were generated by s.c. transplantation of
human colorectal HT29 (n = 21), HCT116 (n = 7) and
Score plot of PC1 versus PC3 from PCA of the spin-echo spectra from untreated HT29, HCT116, SW620 xenografts and rec- tal cancer biopsies (A) Figure 4
Score plot of PC1 versus PC3 from PCA of the spin-echo spectra from untreated HT29, HCT116, SW620 
xenografts and rectal cancer biopsies (A). Loading profile of PC3 (B).Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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Score plot of PC1 and PC2 from principal component analysis of the spectral region 4.7 - 0.5 ppm from spin-echo MAS MR  spectra of irradiated and untreated HT29 xenografts with color coding according to untreated (red)/irradiated (yellow) (A) and  amount of necrosis in the samples (B) Figure 5
Score plot of PC1 and PC2 from principal component analysis of the spectral region 4.7 - 0.5 ppm from spin-
echo MAS MR spectra of irradiated and untreated HT29 xenografts with color coding according to untreated 
(red)/irradiated (yellow) (A) and amount of necrosis in the samples (B). The corresponding loading profile of PC1 
(C). Each point in (A) and (B) represents a single tumor tissue sample.Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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Correlation between measured necrotic fraction and predicted necrotic fraction based on the samples metabolic profile (r =  0.96 p < 0.001 for training and r = 0.76, p < 0.002 for validation) (A) Figure 6
Correlation between measured necrotic fraction and predicted necrotic fraction based on the samples meta-
bolic profile (r = 0.96 p < 0.001 for training and r = 0.76, p < 0.002 for validation) (A). Score plot of PC1 versus PC2 
from PLS calibration of necrotic fraction to single-pulse spectral data for untreated and irradiated HT29 xenografts (B) and the 
corresponding loading profile of PC1 (C).Molecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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SW620 (n = 5) tumor tissue fragments (~2 × 2 × 2 mm3)
into the flanks of athymic nude mice. The animals (20–30
g, 7–9 weeks old) were bred at the animal department of
our institute and kept under specific pathogen-free condi-
tions at constant temperature (22 – 24°C) and humidity
(30 – 50%). The animals were given sterilized food and
tap water ad libitum. The experiment was approved by the
National Committee on Research on Animal Care and
executed according to the Interdisciplinary Principles and
Guidelines for the Use of Animals in Research, Marketing
and Education (New York Academy of Science, New York,
NY).
Eight of the HT29 xenografts were given a single dose of
15 Gy using a 60Co unit (Mobaltron 80, TEM Instruments,
Crawley, United Kingdom) with a dose rate of 0.6 Gy/
min. The animals were anesthetized with a 25 mg/kg s.c.
injection of a mixture of tiletamine 2.4 mg/ml and
zolazepam 2.4 mg/ml (Zoletil vet®, Virbac Laboratories,
Carros, France), xylazine 3.8 mg/ml (Narcoxyl vet, Roche,
Basel, Switzerland) and butorphanol 0.1 mg/ml (Torbug-
esic, Fort Dodge Laboratories, Fort Dodge, Iowa, USA).
Radiation dose deposition to other parts of the animals
was minimized by placing the animals in the outer cor-
ners of the 10 × 10 cm2 radiation field. Five millimeter
buildup bolus was placed on top of the tumors to give
maximum dose deposition within the tumor volume. Ter-
moluminescence (TLD) chips monitored the individual
tumor doses.
All mice were sacrificed with neck dislocation six to nine
weeks after inoculation when the mice were bearing 500
mm3 to 900 mm3 subcutaneous tumors. The tumors were
immediately excised and put on liquid nitrogen, and fur-
ther stored at -70°C until HR MAS MRS analysis.
Rectal cancer biopsies
Tumor biopsies from 10 patients (7 men and 3 women)
with histologically proven rectal adenocarcinoma (T2-4,
N0-2, M0) were included in this study. The median age
was 58 years (range; 43–73). Tumor biopsies were imme-
diately frozen in liquid nitrogen, labeled and further
stored at -70°C until HR MAS MRS analysis. The patients
gave written informed consent to participate in the study
that was approved by the local ethics committee.
HR MAS MRS
Prior to HR MAS MRS analysis, all samples were cut
(mean weight; xenografts: 15.68 mg, patient samples:
18.19 mg) to fit a MAS rotor (50 µL, 4 mm o.d.). Phos-
phate buffered saline (PBS, 40 µL)) in D2O (deuterium
lock reference) containing trimethylsilyl tetradeuteropro-
pionic acid (TSP) as a chemical shift reference was added
to the sample. Excess buffer was removed in the rotor
assembling procedure. Sample preparation took approxi-
mately 10 minutes and was performed on top of ice
blocks.
HR MAS 1H MR spectra were recorded using a Bruker
Avance DRX600 spectrometer equipped with a 1H/13C
MAS probe that had the gradient aligned with the magic
angle axis (Bruker BioSpin GmbH, Germany). Samples
were spun at 5 kHz using an instrumental temperature set-
ting of 4°C.
Two one-dimensional acquisitions were performed for all
samples. First, single-pulse spectra (zgpr; Bruker) were
obtained using 3.0 s of water presaturation and a 60° flip
angle over a sweep width of 20 ppm. The free induction
decay (FID) was acquired during 1.36 s and collected into
32 K points, giving a repetition time of 4.36 s. A total of
32 FIDs were recorded and averaged. Thereafter, Carr-Pur-
cell-Meiboom-Gill (CPMG) spin-echo experiment (cpm-
gpr; Bruker) was performed using 2.0 s of water
suppression prior to a 90° excitation pulse. Reduction of
signal from metabolites with short T2 relaxation (T2- filter-
ing) was obtained using a delay of 1 ms repeated 136
times resulting in a 285 ms effective echo time. One hun-
dred twenty-eight FIDs over a frequency region of 16.7
ppm were collected into 32 K points, resulting in an acqui-
sition time of 1.64 s. The repetition time was 3.93 s. Raw
data of both single-pulse and spin-echo spectra were mul-
tiplied with a 0.3 Hz exponential line broadening before
Fourier transformation and application of a second order
linear baseline correction.
Homonuclear correlated spectra (COSY) were obtained
using a standard pulse program including gradients and
water presaturation (cosygpr, Bruker). 52 transients per
increment for 512 increments were collected into 2 K data
points. A spectra width of 13.3 ppm was used in both
dimensions. The time domain data were zero-filled and
multiplied with a sine function in both dimensions before
Fourier transformation.
Histology
Immediately after acquisition of HR MAS MR spectra all
specimens were fixed in 10% formalin and embedded in
paraffin. One 5 µm cross-section was cut from each block,
stained with haematoxylin, erythrosine and saffron, and
examined microscopically with respect to viable tissue,
necrosis and fibrosis by an experienced pathologist. Anal-
ysis of variance (ANOVA, SPSS version 13.0 Science, Chi-
cago, IL, USA) was used for comparing group means.
Multivariate analysis
Separate matrices of single-pulse and spin-echo spectra
were constructed by converting the region of interest (4.7
- 0.5 ppm) to ASCII files. These spectra were peak aligned
[29,30], and imported into the Unscrambler packageMolecular Cancer 2008, 7:33 http://www.molecular-cancer.com/content/7/1/33
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(CAMO process AS, Norway). Baseline offset was
adjusted, and the number of points in the selected spectral
region was reduced to half of its original size by averaging.
Areas in the spectra containing contamination from lubri-
cant gel (human samples) and ethanol (due to laboratory
sterilizing procedures) were removed from the matrices.
The remaining spectral regions were mean normalized
(areas below spectra made equal).
Principal component analysis (PCA) was performed on
matrices of spectra from untreated HCT116, SW620 and
HT29 xenografts (n = 20) and human cancer biopsies (n
= 10) for comparison of their metabolic profiles. Two-
dimensional score plots and loading profiles of the prin-
cipal components (PC) were used to visualize the relative
contribution of individual metabolites to the clustering of
the different spectra. To examine metabolic changes fol-
lowing irradiation, PCA was performed on matrices of
spectra acquired from irradiated and untreated HT29
xenografts. The correlations between the tumors meta-
bolic profiles and necrosis were examined by performing
partial least square (PLS) regression.
All model calibrations (PCA and PLS) were performed
both on matrices of spin-echo and single-pulse spectra,
with mean centered data and full cross-validation (leave-
one-out). In the PLS modeling, the number of PCs to
retain in the model was determined by minimizing the
total residual y-variance and the root mean square of pre-
diction. Pearson's correlation analysis was used to deter-
mine the connection between MR predicted and
histological measured necrotic fraction.
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